(Q34506465)

2 August 2017

title

Paclitaxel and tamoxifen: An active regimen for patients with metastatic melanoma (English)

1 reference

2 August 2017

1 reference

1 reference

1 reference

Nathan FE

1

1 reference

2 August 2017

Berd D

series ordinal

2

1 reference

2 August 2017

Sato T

series ordinal

3

1 reference

2 August 2017

Mastrangelo MJ

series ordinal

4

1 reference

2 August 2017

language of work or name

English

0 references

publication date

1 January 2000

1 reference

2 August 2017

number of pages

9

1 reference

based on heuristic

inferred from page(s)

published in

Cancer

1 reference

2 August 2017

volume

88

1 reference

2 August 2017

issue

1

1 reference

2 August 2017

page(s)

79-87

1 reference

Development of a biochemotherapy regimen with concurrent administration of cisplatin, vinblastine, dacarbazine, interferon alfa, and interleukin-2 for patients with metastatic melanoma.

2 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0142%2820000101%2988%3A1%3C79%3A%3AAID-CNCR12%3E3.0.CO%3B2-L

Plant antitumor agents. VI. The isolation and structure of taxol, a novel antileukemic and antitumor agent from Taxus brevifolia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0142%2820000101%2988%3A1%3C79%3A%3AAID-CNCR12%3E3.0.CO%3B2-L

Modulation of induced resistance to adriamycin in two human breast cancer cell lines with tamoxifen or perhexiline maleate

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0142%2820000101%2988%3A1%3C79%3A%3AAID-CNCR12%3E3.0.CO%3B2-L

Differential modulation of doxorubicin toxicity to multidrug and intrinsically drug resistant cell lines by anti-oestrogens and their major metabolites

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0142%2820000101%2988%3A1%3C79%3A%3AAID-CNCR12%3E3.0.CO%3B2-L

Phase I trial of taxol given as a 24-hour infusion every 21 days: responses observed in metastatic melanoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0142%2820000101%2988%3A1%3C79%3A%3AAID-CNCR12%3E3.0.CO%3B2-L

A phase I trial of taxol given by a 6-hour intravenous infusion

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0142%2820000101%2988%3A1%3C79%3A%3AAID-CNCR12%3E3.0.CO%3B2-L

The importance of tamoxifen to a cisplatin-containing regimen in the treatment of metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0142%2820000101%2988%3A1%3C79%3A%3AAID-CNCR12%3E3.0.CO%3B2-L

Toremifene: pharmacologic and pharmacokinetic basis of reversing multidrug resistance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0142%2820000101%2988%3A1%3C79%3A%3AAID-CNCR12%3E3.0.CO%3B2-L

Modulatory effect of tamoxifen and ICI 182,780 on adriamycin resistance in MCF-7 human breast-cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0142%2820000101%2988%3A1%3C79%3A%3AAID-CNCR12%3E3.0.CO%3B2-L

Synergistic antiproliferative activity of tamoxifen and docetaxel on three oestrogen receptor-negative cancer cell lines is mediated by the induction of apoptosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0142%2820000101%2988%3A1%3C79%3A%3AAID-CNCR12%3E3.0.CO%3B2-L

High-dose oral tamoxifen, a potential multidrug-resistance-reversal agent: phase I trial in combination with vinblastine

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0142%2820000101%2988%3A1%3C79%3A%3AAID-CNCR12%3E3.0.CO%3B2-L

Intermittent high-dose tamoxifen as a potential modifier of multidrug resistance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0142%2820000101%2988%3A1%3C79%3A%3AAID-CNCR12%3E3.0.CO%3B2-L

Reversal of multidrug resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0142%2820000101%2988%3A1%3C79%3A%3AAID-CNCR12%3E3.0.CO%3B2-L

A phase II trial of taxol in metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0142%2820000101%2988%3A1%3C79%3A%3AAID-CNCR12%3E3.0.CO%3B2-L

A phase II study of taxol in patients with malignant melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0142%2820000101%2988%3A1%3C79%3A%3AAID-CNCR12%3E3.0.CO%3B2-L

European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: high-dose versus low-dose and long versus short infusion

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0142%2820000101%2988%3A1%3C79%3A%3AAID-CNCR12%3E3.0.CO%3B2-L

10.1002/(SICI)1097-0142(20000101)88:1<79::AID-CNCR12>3.0.CO;2-L

21 January 2018

Identifiers

DOI

1 reference

2 August 2017

1 reference